Log in

Transjugular intrahepatic portosystemic shunt in patients with autoimmune hepatitis-induced cirrhosis and variceal bleeding

  • Interventional Radiology
  • Published:
Abdominal Radiology Aims and scope Submit manuscript

Abstract

Background and Aim

An increasing number of patients with autoimmune hepatitis (AIH)-induced cirrhosis and variceal bleeding are currently referred for transjugular intrahepatic portosystemic shunt (TIPS). The aim of this study was to evaluate the safety and efficacy of TIPS in such patients, and to compare these results with data from patients with hepatitis B virus (HBV)-induced cirrhosis.

Materials and Methods

This retrospective study consisted of 211 patients between August 2016 and May 2021, and patients were allocated to AIH (n = 35) and HBV (n = 176) groups according to the etiology of the cirrhosis. The primary endpoint was mortality after TIPS use; the secondary endpoints were recurrent bleeding, overt hepatic encephalopathy (OHE), shunt dysfunction, and dynamic changes in liver function over time.

Results

During a median follow-up period of 27 months, 23 (10.9%) patients died, 22 (10.4%) experienced recurrent bleeding, 50 (23.7%) experienced OHE, and 25 (11.8%) developed shunt dysfunction. Compared with the HBV group, the AIH group exhibited a similar mortality risk (adjusted hazard ratio, HR 1.199; 95% confidence interval, CI 0.367–3.917; p = 0.764), OHE (adjusted HR 1.023, 95% CI 0.483–2.167, p = 0.954), and shunt dysfunction (adjusted HR 0.862, 95% CI 0.285–2.610, p = 0.792); but a higher risk of recurrent bleeding (adjusted HR 2.731, 95% CI 1.112–6.708, p = 0.028). The dynamic changes in liver function manifested an initial trend toward deterioration, and then subsequent recovery in both the AIH and HBV groups.

Conclusions

TIPS is a safe and effective treatment, and should be considered for those patients with AIH-induced cirrhosis and variceal bleeding.

Graphical abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Manns MP, Lohse AW, Vergani D. Autoimmune hepatitis--Update 2015. J Hepatol 2015;62:S100-11.

    Article  Google Scholar 

  2. Yang F, Wang Q, Bian Z, et al. Autoimmune hepatitis: East meets west. J Gastroenterol Hepatol 2015;30:1230-6.

    Article  Google Scholar 

  3. Trivedi PJ, Cullen S. Autoimmune hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Dig Dis Sci 2011;56:276-8.

    Article  Google Scholar 

  4. Moon AM, Spiritos Z, King LY, et al. Immunosuppression in Autoimmune Hepatitis: Is There an End Game? Am J Gastroenterol 2020;115:498-501.

    Article  Google Scholar 

  5. Bodzin AS, Baker TB. Liver Transplantation Today: Where We Are Now and Where We Are Going. Liver Transpl 2018;24:1470-1475.

    Article  Google Scholar 

  6. Bureau C, Thabut D, Oberti F, et al. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites. Gastroenterology 2017;152:157-163.

    Article  Google Scholar 

  7. Garcia-Pagan JC, Caca K, Bureau C, et al. Early Use of TIPS in Patients with Cirrhosis and Variceal Bleeding. New England Journal of Medicine 2010;362:2370-2379.

    Article  CAS  Google Scholar 

  8. Mack CL, Adams D, Assis DN, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology 2020;72:671-722.

    Article  Google Scholar 

  9. Nguyen MH, Wong G, Gane E, et al. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev 2020;33.

  10. Liu J, Ma J, Yang C, et al. Impact of TIPS on Splenic Volume and Thrombocytopenia. AJR Am J Roentgenol 2021;216:698-703.

    Article  Google Scholar 

  11. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014;60:715-35.

    Article  Google Scholar 

  12. Lv Y, He C, Wang Z, et al. Association of Nonmalignant Portal Vein Thrombosis and Outcomes after Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis. Radiology 2017;285:999-1010.

    Article  Google Scholar 

  13. Kumar R, Kerbert AJC, Sheikh MF, et al. Determinants of mortality in patients with cirrhosis and uncontrolled variceal bleeding. J Hepatol 2021;74:66-79.

    Article  Google Scholar 

  14. Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021;73:366-413.

    Article  Google Scholar 

  15. Dalal AA, Duh MS, Gozalo L, et al. Dose-Response Relationship Between Long-Term Systemic Corticosteroid Use and Related Complications in Patients with Severe Asthma. J Manag Care Spec Pharm 2016;22:833-47.

    PubMed  Google Scholar 

  16. Lv Y, Yang Z, Liu L, et al. Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial. Lancet Gastroenterol Hepatol 2019;4:587-598.

    Article  Google Scholar 

  17. Holster IL, Tjwa ET, Moelker A, et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + beta-blocker for prevention of variceal rebleeding. Hepatology 2016;63:581-9.

    Article  CAS  Google Scholar 

  18. Liu J, Zhou C, Wang Y, et al. The combination of Child-Pugh score and quantitative CT-based spleen volume could predict the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation. Abdom Radiol (NY) 2021;46:3464-3470.

    Article  Google Scholar 

  19. Kloster ML, Ren A, Shah KY, et al. High Incidence of Hepatic Encephalopathy After Viatorr Controlled Expansion Transjugular Intrahepatic Portosystemic Shunt Creation. Dig Dis Sci 2021;66:4058-4062.

    Article  Google Scholar 

  20. Yang Y, Fu S, Cao B, et al. Prediction of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt treatment: a cohort study. Hepatol Int 2021;15:730-740.

    Article  Google Scholar 

  21. Jansen C, Moller P, Meyer C, et al. Increase in liver stiffness after transjugular intrahepatic portosystemic shunt is associated with inflammation and predicts mortality. Hepatology 2018;67:1472-1484.

    Article  CAS  Google Scholar 

  22. Luca A, Miraglia R, Maruzzelli L, et al. Early Liver Failure after Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis with Model for End-Stage Liver Disease Score of 12 or Less: Incidence, Outcome, and Prognostic Factors. Radiology 2016;280:622-629.

    Article  Google Scholar 

  23. Bettinger D, Schultheiss M, Boettler T, et al. Procedural and shunt-related complications and mortality of the transjugular intrahepatic portosystemic shunt (TIPSS). Alimentary Pharmacology & Therapeutics 2016;44:1051-1061.

    Article  CAS  Google Scholar 

  24. Gulberg V, Haag K, Rossle M, et al. Hepatic arterial buffer response in patients with advanced cirrhosis. Hepatology 2002;35:630-4.

    Article  Google Scholar 

  25. Gioia S, Ridola L, Cristofaro L, et al. The improvement in body composition including subcutaneous and visceral fat reduces ammonia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Liver Int 2021;41:2965-2973.

    Article  CAS  Google Scholar 

  26. Benmassaoud A, Roccarina D, Arico F, et al. Sarcopenia Does Not Worsen Survival in Patients With Cirrhosis Undergoing Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites. Am J Gastroenterol 2020;115:1911-1914.

    Article  Google Scholar 

  27. Yang Z, Han G, Wu Q, et al. Patency and clinical outcomes of transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stents versus bare stents: a meta-analysis. J Gastroenterol Hepatol 2010;25:1718-25.

    Article  Google Scholar 

  28. Saad WE, Darwish WM, Davies MG, et al. Stent-grafts for transjugular intrahepatic portosystemic shunt creation: specialized TIPS stent-graft versus generic stent-graft/bare stent combination. J Vasc Interv Radiol 2010;21:1512-20.

    Article  Google Scholar 

Download references

Funding

Medical Science and Technology Project of Henan Province (LHGJ20190562), National Natural Science Foundation of China (81873917).

Author information

Authors and Affiliations

Authors

Contributions

Conceptualization: BX; Methodology: CW and JL; Data collection: JY, SJ and YW; Data analysis and interpretation: CY; Software: CY and YB; Writing original draft: CW and WY; Writing review and editing: YC and SH.

Corresponding author

Correspondence to Bin **ong.

Ethics declarations

Conflict of interest

The authors of this manuscript declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, C., Liu, J., Yao, J. et al. Transjugular intrahepatic portosystemic shunt in patients with autoimmune hepatitis-induced cirrhosis and variceal bleeding. Abdom Radiol 47, 1464–1472 (2022). https://doi.org/10.1007/s00261-022-03465-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-022-03465-w

Keywords

Navigation